Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 32Recruiting 14Terminated 12Active not recruiting 7Unknown 6Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Melanoma 11Triple Negative Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Neoplasms 7Head and Neck Neoplasms 7Multiple Myeloma 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Pancreatic Neoplasms 5Lung Neoplasms 4Recurrence 3Prostatic Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Kidney Neoplasms 2Inflammatory Breast Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Urothelial Cancer 1Thyroid Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Spinocerebellar Degenerations 1

Interventions

Sorafenib 13Radiosurgery 9spartalizumab 7lenvatinib 7Oxaliplatin 6Gemcitabine 5Fluorouracil 5Radiotherapy 4Cisplatin 4Bevacizumab 4atezolizumab 3Leucovorin 3Folfox protocol 3Doxorubicin 3gadolinium ethoxybenzyl DTPA 2fludarabine 2cabozantinib 2Nivolumab 2Mitomycin 2Electroporation 2Cyclophosphamide 2Chemoembolization, Therapeutic 2tremelimumab 1toripalimab 1tocilizumab 1tislelizumab 1temsirolimus 1tazemetostat 1sitravatinib 1pirarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Hepatocellular × pembrolizumab × Clear all
NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1/2 Withdrawn
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡